美通社

2024-08-21 09:00

Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption

New Veeva Pulse findings show congresses and early-career experts have the strongest influence on patient outcomes

SINGAPORE, Aug. 21, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today revealed that targeted pre-launch scientific outreach maximizes medical affairs teams' impact on treatment adoption in the latest Veeva Pulse Field Trends Report. The analysis shows biopharmas investing in pre-launch scientific activities and prioritizing congresses gain 40% faster treatment adoption than those that invested less. Early-career experts are also more open to digital engagement and four times more likely to start patients on a new treatment.

In Asia, healthcare professionals (HCPs) are prioritizing in-person engagement, outperforming other channels like video, email, phone, and text or in-app chat.

Asia also recorded the highest video usage rate globally at 56%, compared to the US, EU, and LATAM regions, showing a preference for more in-depth engagement.

HCPs are turning to biopharmas to help distill rapidly evolving scientific evidence around new innovative medicines and complex diseases. By focusing pre-launch activity around clinical guidelines, publications, and congresses with a new group of stakeholders, medical affairs teams can reach key HCPs to improve treatment decisions.

"Gone are the days when medical could just focus on the top-tier scientific thought leaders," said Angela Smart, director of global medical excellence and operations at ADVANZ PHARMA. "The range of stakeholders has broadened, and it's imperative to expand our engagement strategies beyond traditional experts." 

The latest analysis from Veeva Pulse finds that:

  • Targeted pre-launch scientific activities speed treatment adoption: By engaging key experts at congresses, helping develop clinical guidelines, and securing coverage in publications before launch, companies see 40% faster treatment adoption than those that don't. This demonstrates that more resources for medical teams during this stage can boost launch success.

 


 

  • Congress activity has the strongest influence on clinical decisions: Higher investment in pre-launch congress activities has the most influence on treatment after approval. Congresses, and the digital discussions that follow, help increase scientific awareness and drive impactful medical conversations more than investment in clinical guidelines and publications.

 


 

  • Engaging early-career HCPs increases new treatment uptake: These digitally-savvy emerging experts are four times more likely to start patients on a new treatment. They are also five times more likely to speak at congresses, 11 times more likely to engage digitally, and seven times more likely to get published.

  • In Asia, in-person activity was the preferred channel of communication, showing HCPs' need for in-depth engagement: In the past quarter, in-person activity represented 82% of the channel mix, outperforming other channels such as email, phone, video, and text or chat. This trend was consistent across the industry, from smaller biotechs to large biopharmas.

  • Compliant content continues to play a critical role in HCP engagement: Closed-loop marketing (CLM) interactive visual aid usage increased for both in-person and video engagement channels, demonstrating the increasing importance of leveraging content to create more personalized interactions with HCPs.

"It is key that field teams continue to meet the needs of HCPs by providing important information to understand complex new medicines through the right channels. Our Pulse data has shown that effectively communicating scientific evidence before launch has a significant impact in driving quicker treatment adoption. HCP needs are evolving, and it is important to leverage data to inform strategies towards driving efficiency and engagement," said Shafi Hussain, Veeva Asia business consulting head. 

About the Veeva Pulse Field Trends Report
Analyzing over 600 million HCP interactions and activities annually from more than 80% of commercial biopharma field teams worldwide, the Veeva Pulse Field Trends Report is the largest industry benchmark of its kind on HCP engagement. The analysis compiles real-time transactional data recorded in Veeva CRM and Veeva data products to deliver a view of engagement activity across life sciences. Indexed by Veeva quarterly, the data will help companies effectively and accurately benchmark performance to set the right, actionable goals for continued growth and impact.

Additional Information
To download a copy of the Veeva Pulse Field Trends Report, visit: veeva.com/FieldTrends
Learn more about Veeva Business Consulting: veeva.com/BusinessConsulting
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 35 and 36), and in our subsequent SEC filings, which you can access at sec.gov.

source: Veeva Systems

【你點睇?】新一份預算案公布,多項開源節流措施推出,你認為哪一項措施最能達致改善政府財赤目標?► 立即投票

人氣文章
最近7天
1
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
2
財政預算案2025 | 重點文字直播/Youtube直播(稍後送上懶人包)
3
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
4
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
5
高息定存 | 一周高息合集,3個月5厘之選有邊間?6個月最高3.55厘
6
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
7
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
8
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
9
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
10
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
11
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
12
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
13
高息定存 | 信銀國際12個月港元定存高達3.5厘
14
2025強積金整合獎賞一覽 轉供應商最多竟然可賺!?
15
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
16
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
17
民營企業座談會 | 習近平在京出席民營企業座談會
18
AI | 追捧DeepSeek,全球對沖基金棄印度投中國
19
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
20
David Webb:因病情惡化,將有序結束個人財經網站
21
比特幣 | 亞洲時段虛擬貨幣大幅下跌,31萬人爆倉
22
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
23
譚仔 | 譚仔國際日資大股東溢價76%建議私有化今復牌,上市不足三年半
24
港股 | 蕭猷華:恒指升勢可持續?
25
美股收盤 | 美股三大指數收市報跌,道指跌近750點
26
神州經脈 | 習近平:經濟政策不會變,民企大顯身手正當其時
27
神州經脈 | 中國減持美債,螞蟻入局具身智能,70城樓價向好
28
港股 | 蕭猷華:恒指上半年目標25000點
29
隱瞞「賣殼」欺詐罪成,詹培忠判囚34個月,詹劍崙囚37個月
30
高息定存 | 銀行加港元存息,東亞3個月加至3.5厘10萬起存
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

2025-26年度財政預算案

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老